Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Kevin J HarringtonLillian L Siu

Abstract

Purpose The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec (T-VEC), an oncolytic immunotherapy approved for advanced melanoma, in combination with pembrolizumab may yield enhanced antitumor activity over either agent alone. Experimental Design This was a phase 1b/3, multicenter trial testing intratumoral T-VEC combined with intravenous pembrolizumab in R/M HNSCC refractory to platinum-based chemotherapy. For phase 1b, primary endpoint was incidence of dose-limiting toxicity (DLT). Key secondary endpoints included objective response rate and progression-free survival (PFS) per irRECIST, overall survival (OS), and safety. Results Thirty-six patients were enrolled into the phase 1b study. The data cutoff date was August 28, 2018. Median follow up was 5.8 months (range: 0.3-24.2). One DLT of T-VEC-related fatal arterial hemorrhage was reported. Twenty (55.6%) and 21 (58.3%) patients experienced adverse events (AEs) related to T-VEC and pembrolizumab, respectively. Besides the DLT, there were no treatment-related fatal AEs. A confirmed partial response was observed in 5 (13.9...Continue Reading

References

Jul 4, 2007·International Immunology·Taku Okazaki, Tasuku Honjo
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Jun 10, 2010·The New England Journal of Medicine·K Kian AngMaura L Gillison
Jul 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin J HarringtonChristopher M Nutting
Jun 30, 2012·The American Journal of Surgical Pathology·Richard C JordanMaura L Gillison
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Jul 9, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul M HarariKian Ang
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Mar 6, 2016·Mayo Clinic Proceedings·Shanthi Marur, Arlene A Forastiere
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Igor PuzanovRobert H I Andtbacka
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
Oct 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason ChesneyHoward L Kaufman

❮ Previous
Next ❯

Citations

Oct 1, 2020·International Journal of Molecular Sciences·Masakazu Hamada, Yoshiaki Yura
Jul 3, 2021·Cells·Norah AldrakNada Zaidan
Jul 2, 2021·Annals of Surgical Oncology·Flora YanAndrew T Day
Aug 3, 2021·Frontiers in Oncology·Rebecca R PharaonVictoria M Villaflor
Aug 8, 2021·International Journal of Molecular Sciences·Chang-Gon KimHong-Jae Chon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.